178 related articles for article (PubMed ID: 7898254)
1. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies.
Dams ET; van der Meer JW
Lancet; 1995 Apr; 345(8953):864. PubMed ID: 7898254
[No Abstract] [Full Text] [Related]
2. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
Gardulf A; Andersen V; Björkander J; Ericson D; Frøland SS; Gustafson R; Hammarström L; Jacobsen MB; Jonsson E; Möller G
Lancet; 1995 Feb; 345(8946):365-9. PubMed ID: 7845120
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin therapy: methods of delivery.
Ballow M
J Allergy Clin Immunol; 2008 Nov; 122(5):1038-9. PubMed ID: 18804269
[No Abstract] [Full Text] [Related]
4. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
[TBL] [Abstract][Full Text] [Related]
5. [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution].
Haddad L; Perrinet M; Parent D; Leroy-Cotteau A; Toguyeni E; Condette-Wojtasik G; Hachulla E
Rev Med Interne; 2006 Dec; 27(12):924-6. PubMed ID: 17011081
[TBL] [Abstract][Full Text] [Related]
6. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous immunoglobulin for patients with antibody deficiency.
Helbert M; Farragher A
Br J Hosp Med (Lond); 2007 Apr; 68(4):206-10. PubMed ID: 17465102
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
9. New choices for treatment with subcutaneous immunoglobulins.
Pleguezuelo DE; Sánchez-Ramón S
Med Clin (Barc); 2017 Jan; 148(2):86-90. PubMed ID: 27919413
[No Abstract] [Full Text] [Related]
10. [Use of intravenous and subcutaneous human immunoglobulins].
Ramus B; Benbrahim O; Chérin P
Soins; 2019 Mar; 64(833):13-18. PubMed ID: 30879622
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomics of immunoglobulins in primary immunodeficiency.
Simoens S
Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):375-86. PubMed ID: 19670998
[TBL] [Abstract][Full Text] [Related]
12. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.
Perraudin C; Bourdin A; Spertini F; Berger J; Bugnon O
J Clin Immunol; 2016 Jul; 36(5):502-10. PubMed ID: 27139500
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin replacement therapy by slow subcutaneous infusion.
Berger M; Cupps TR; Fauci AS
Ann Intern Med; 1980 Jul; 93(1):55-6. PubMed ID: 7396316
[No Abstract] [Full Text] [Related]
14. [Immunoglobulins and immune deficiency: methods of administration].
Suarez F
Rev Med Interne; 2005 Oct; 26 Spec No 1():25-8. PubMed ID: 16475260
[No Abstract] [Full Text] [Related]
15. IgG replacement therapy, no size fits all.
Bonilla FA
Clin Immunol; 2011 May; 139(2):107-9. PubMed ID: 21420364
[No Abstract] [Full Text] [Related]
16. [Replacement therapy with subcutaneous immunoglobulin in primary immunodeficiency in children].
Pac M
Pol Merkur Lekarski; 2011 Jun; 30(180):413-6. PubMed ID: 21751550
[TBL] [Abstract][Full Text] [Related]
17. European surveillance of immunoglobulin safety--results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries.
Quinti I; Pierdominici M; Marziali M; Giovannetti A; Donnanno S; Chapel H; Bjorkander J; Aiuti F;
Clin Immunol; 2002 Sep; 104(3):231-6. PubMed ID: 12217332
[TBL] [Abstract][Full Text] [Related]
18. Novel aspects of hypogammaglobulinemic states: subcutaneous immunoglobulin treatment.
Grunebaum E; Levy Y; Shoenfeld Y
Isr Med Assoc J; 2002 Apr; 4(4):288-9. PubMed ID: 12001706
[No Abstract] [Full Text] [Related]
19. Update on the use of immunoglobulin in human disease: A review of evidence.
Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance.
Högy B; Keinecke HO; Borte M
Eur J Health Econ; 2005 Mar; 6(1):24-9. PubMed ID: 15480920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
